Can Descovy be used for pre-exposure prophylaxis (PrEP) in HIV?
Medically reviewed by Drugs.com. Last updated on Oct 3, 2019.
Descovy was first approved in April 2016 in combination with other antiretoviral drugs to treat HIV-1 infection in adults and pediatric patients 12 years of age and older.
PrEP is an HIV prevention method in which people who do not have HIV take medicine on a daily basis to reduce their risk of getting HIV if they are exposed to the virus.
Descovy for PrEP is indicated for use in at-risk, adult and adolescent HIV-negative men and transgender women (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection.
Descovy is the second medicine to be FDA approved for PrEP, after the approval of Truvada (emtricitabine and tenofovir disoproxil fumarate) in July 2012.
Related Medical Questions
- Truvada vs Descovy: How do they compare for HIV and PrEP?
- What is the difference between Biktarvy and Descovy?
- Modafinil vs Adderall: What's the difference?
- Which medicines should not be taken with Biktarvy?
- Can Leronlimab (PRO 140) be used to treat COVID-19 (coronavirus)?
- What if I miss a dose of Biktarvy?
- How fast or how long does it take Biktarvy to work?
- Descovy Information for Consumers
- Descovy Information for Healthcare Professionals (includes dosage details)
- Side Effects of Descovy (detailed)